23:17 , Oct 3, 2018 |  BC Innovations  |  Translation in Brief

New Therapeutic Targets and Biomarkers: September 2018

New Therapeutic Targets and Biomarkers: September 2018 Select top therapeutic targets and biomarkers covered by BioCentury or added to the BCIQ database in September. Therapeutic targets are defined as any protein, gene or other molecule that...
19:44 , Sep 14, 2018 |  BioCentury  |  Emerging Company Profile

Laekna’s jumping off place

Chinese biotech Laekna Therapeutics Shanghai Co. Ltd. is jump-starting its pipeline with a trio of clinical cancer compounds from Novartis AG. The safety of the lead candidate and its potential to synergize with the other...
22:07 , Sep 13, 2018 |  BC Innovations  |  Translation in Brief

New Therapeutic Targets and Biomarkers: August 2018

New Therapeutic Targets and Biomarkers: August 2018 Select top therapeutic targets and biomarkers covered by BioCentury or added to the BCIQ database in August 2018. Therapeutic targets are defined as any protein, gene or other molecule...
19:32 , Sep 10, 2018 |  BC Innovations  |  Distillery Therapeutics

Endocrine/metabolic

INDICATION: Metabolic Mouse studies suggest ASL gene therapy could help treat argininosuccinic aciduria, which is caused by ASL mutations. In a mouse model of the disease, an adeno-associated viral (AAV) serotype 8 (AAV8) vector encoding ASL...
18:51 , Aug 31, 2018 |  BC Week In Review  |  Clinical News

Esperion combo lowers LDL-C in Phase III for high-risk ASCVD

Esperion Therapeutics Inc. (NASDAQ:ESPR) said its bempedoic acid/ezetimibe combination pill met the primary endpoint of reducing LDL-C in the Phase III 1002-053 trial to treat hypercholesterolemia in high-risk atherosclerotic cardiovascular disease (ASCVD) patients on maximally...
19:45 , Aug 27, 2018 |  BC Extra  |  Clinical News

Esperion combo lowers LDL-C in high-risk ASCVD

Esperion Therapeutics Inc. (NASDAQ:ESPR) said its bempedoic acid/ezetimibe combination pill met the primary endpoint of reducing LDL-C in the Phase III 1002-053 trial to treat hypercholesterolemia in high-risk atherosclerotic cardiovascular disease (ASCVD) patients on maximally...
23:48 , Aug 8, 2018 |  BC Innovations  |  Distillery Therapeutics

Cardiovascular

INDICATION: Thrombosis In vitro, cell culture and mouse studies identified a choline-based inhibitor of bacterial cutC that could help treat thrombosis. Chemical synthesis of choline analogs, and in vitro and bacterial cell-based enzymatic activity assays...
20:38 , Aug 6, 2018 |  BC Extra  |  Preclinical News

Modifying microbes for clot prevention

Cleveland Clinic researchers have developed inhibitors of bacterial choline trimethylamine-lyase (bacterial cutC), an enzyme found in commensal gut microbes, that could help treat thrombosis by targeting bacterial metabolic activity without killing the microbes. Previous studies identified...
18:22 , Jun 13, 2018 |  BC Innovations  |  Distillery Therapeutics

Infectious disease

INDICATION: Candida HEK cells engineered to synthesize and secrete bacterial AI-2 could help treat candidiasis. The cells are generated by transfecting HEK cells with two constructs: a sensor unit, based on formyl peptide receptor 1 (FPR1),...
18:57 , May 30, 2018 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Prostate cancer In vitro, cell culture and mouse studies suggest inhibiting the DNAJ/Hsp70 chaperone axis could help treat castration-resistant prostate cancer (CRPC). Screening of a library of chalcone analogs and testing in cell-based signaling assays...